

5-1-2018

Acquired Resistance Mutations to EGFR Treatment in Non-Small Cell Lung Cancer


Benjamen Schoenberg

Thomas Jefferson University, benjamen.schoenberg@jefferson.edu

Gregory Omerza, PhD

Thomas Jefferson University, gregory.omerza@jefferson.edu

Let us know how access to this document benefits you

Follow this and additional works at: <http://jdc.jefferson.edu/phsrs> Part of the [Medical Anatomy Commons](#), [Medical Cell Biology Commons](#), and the [Medical Pathology Commons](#)

Recommended Citation

Schoenberg, Benjamen and Omerza, PhD, Gregory, "Acquired Resistance Mutations to EGFR Treatment in Non-Small Cell Lung Cancer" (2018). *Pathology Honors Program Student Research Symposium*. Poster 36.<http://jdc.jefferson.edu/phsrs/36>

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's [Center for Teaching and Learning \(CTL\)](#). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Pathology Honors Program Student Research Symposium by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Acquired Resistance Mutations to EGFR Treatment in Non-Small Cell Lung Cancer

Benjamin Schoenberg and Gregory Omerza

Clinical Genomic and Molecular Pathology Laboratory, Thomas Jefferson University Hospital

Non-small cell lung cancer (NSCLC) is currently the number one cause of cancer death in the United States for both men and women.¹ Mutations in the epidermal growth factor receptor (EGFR) gene are detected in approximately 30% of individuals with advanced NSCLC in Asia and 10-15% in Western countries.² For patients harboring activating EGFR mutations, treatment includes the use of first or second-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs), such as afatinib, gefitinib, or erlotinib.

The purpose of this case study is to review the pathophysiology of the progression of NSCLC in a 63-year-old non-smoking Caucasian woman. The patient presented with worsening back pain for four months, sudden onset of lower extremity weakness, and unintentional 20-pound weight loss. Imaging revealed spinal cord compression, a right upper lung mass with hilar adenopathy, multiple vertebral metastases, adrenal lesions, and a mass in the left lobe of the liver. Transbronchial biopsy of the lung mass in the patient confirmed NSCLC of the adenocarcinoma type. Next Generation Sequencing (NGS) identified an L858R mutation in exon 21 of EGFR, which results in activation of the tyrosine kinase (TK) domain of the EGFR protein product, without the need for ligand binding and a decreased binding affinity for ATP. The patient began daily erlotinib therapy with subsequent regression of disease at four months follow-up. After 12 months on erlotinib the patient developed radiographic progression with a T790M mutation in exon 20, the most common resistance mutation secondary to treatment with first generation TKIs. The patient was subsequently started on the third-generation TKI, osimertinib. After 12 months of treatment the patient developed the EGFR C797S tertiary mutation leading to osimertinib resistance and further progression of the disease.

According to clinical guidelines, all patients with non-squamous NSCLC should be tested for mutations in EGFR. This case study serves as evidence that constant monitoring of EGFR positive patients is essential, as there are multiple ways in which cells develop resistance to TKI treatment.³

Works Cited

1. Cancer Prevalence Worldwide. *Global Cancer Observatory*, World Health Organization, gco.iarc.fr/today/fact-sheets-cancers?cancer=29&type=0&sex=0.
2. Midha, Anita, et al. EGFR Mutation Incidence in Non-Small-Cell Lung Cancer of Adenocarcinoma Histology: a Systematic Review and Global Map by Ethnicity (MutMapII). *American Journal of Cancer Research*, 2015.
3. Marhetti, Antonia, et al. EGFR Mutations in Non-Small-Cell Lung Cancer: Analysis of a Large Series of Cases and Development of a Rapid and Sensitive Method for Diagnostic Screening With Potential Implications on Pharmacologic Treatment." *Journal of Clinical Oncology*, 2005.